JP2003527109A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003527109A5 JP2003527109A5 JP2001561057A JP2001561057A JP2003527109A5 JP 2003527109 A5 JP2003527109 A5 JP 2003527109A5 JP 2001561057 A JP2001561057 A JP 2001561057A JP 2001561057 A JP2001561057 A JP 2001561057A JP 2003527109 A5 JP2003527109 A5 JP 2003527109A5
- Authority
- JP
- Japan
- Prior art keywords
- cyr61
- antibody
- fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150042405 CCN1 gene Proteins 0.000 description 33
- 239000012634 fragment Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000008827 biological function Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/495,448 US6790606B1 (en) | 1996-03-15 | 2000-01-31 | Extracellular matrix signaling molecules |
| US09/495,448 | 2000-01-31 | ||
| US20436400P | 2000-05-15 | 2000-05-15 | |
| US60/204,364 | 2000-05-15 | ||
| US23870500P | 2000-10-06 | 2000-10-06 | |
| US60/238,705 | 2000-10-06 | ||
| PCT/US2001/003267 WO2001055210A2 (en) | 2000-01-31 | 2001-01-31 | Human cyr61 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003527109A JP2003527109A (ja) | 2003-09-16 |
| JP2003527109A5 true JP2003527109A5 (enExample) | 2008-03-13 |
Family
ID=27394650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561057A Pending JP2003527109A (ja) | 2000-01-31 | 2001-01-31 | ヒトｃｙｒ６１ |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1254174B1 (enExample) |
| JP (1) | JP2003527109A (enExample) |
| KR (1) | KR100829842B1 (enExample) |
| CN (1) | CN1447819B (enExample) |
| AT (1) | ATE360643T1 (enExample) |
| AU (2) | AU2001234721B8 (enExample) |
| CA (1) | CA2398660A1 (enExample) |
| DE (1) | DE60128066T2 (enExample) |
| HK (1) | HK1047945B (enExample) |
| IL (3) | IL150885A0 (enExample) |
| WO (1) | WO2001055210A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608970A4 (en) * | 2003-03-31 | 2006-06-14 | Munin Corp | CCN3 COMPOSITIONS AND METHODS |
| JP2004315480A (ja) * | 2003-04-21 | 2004-11-11 | Yoshiyuki Kakehi | 前立腺疾患治療用医薬組成物 |
| TWI356097B (en) * | 2003-06-20 | 2012-01-11 | Munin Corp | Ccn1 compositions and methods |
| US20050177885A1 (en) * | 2004-02-09 | 2005-08-11 | Lau Lester F. | CCN1 transgenic animals |
| WO2006069198A1 (en) | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| JP5153324B2 (ja) | 2005-03-14 | 2013-02-27 | 生化学工業株式会社 | 硬組織形成促進剤 |
| US20100034892A1 (en) | 2006-08-30 | 2010-02-11 | The Trustees Of Columbia University In The City Of New York | Treatment for bone formation disorders by growth factor delivery |
| US8188220B2 (en) * | 2006-12-06 | 2012-05-29 | Sanford-Burnham Medical Research Institute | Methods and compositions related to targeting wounds, regenerating tissue, and tumors |
| ES2412237T3 (es) | 2008-08-01 | 2013-07-10 | Cleveland Biolabs, Inc. | Métodos para tratar lesiones por reperfusión |
| CN101747435B (zh) * | 2008-12-18 | 2013-06-19 | 上海市免疫学研究所 | 一种中和cyr61的单克隆抗体(杂交瘤)及其应用 |
| TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
| KR101187814B1 (ko) * | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| ES2816630T3 (es) | 2014-07-30 | 2021-04-05 | Genome Prot Inc | Composiciones de flagelina y usos |
| US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| CN108840920B (zh) * | 2018-06-19 | 2021-09-28 | 中山大学孙逸仙纪念医院 | 一种人CYR61蛋白Ser167位点磷酸化抗原、抗体及其制备方法和应用 |
| CN111939272B (zh) * | 2020-08-21 | 2023-02-24 | 上海交通大学医学院附属第九人民医院 | Ccn1的用途 |
| CN115058388A (zh) * | 2022-03-14 | 2022-09-16 | 福建医科大学附属协和医院 | 间充质干细胞创面修复优势功能亚群及其鉴定和应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4307552B2 (ja) * | 1996-03-15 | 2009-08-05 | ミューニン コーポレイション | 細胞外マトリックスシグナリング分子 |
-
2001
- 2001-01-31 CA CA002398660A patent/CA2398660A1/en not_active Abandoned
- 2001-01-31 WO PCT/US2001/003267 patent/WO2001055210A2/en not_active Ceased
- 2001-01-31 HK HK03100020.1A patent/HK1047945B/en not_active IP Right Cessation
- 2001-01-31 AT AT01906861T patent/ATE360643T1/de not_active IP Right Cessation
- 2001-01-31 IL IL15088501A patent/IL150885A0/xx unknown
- 2001-01-31 CN CN018076874A patent/CN1447819B/zh not_active Expired - Lifetime
- 2001-01-31 DE DE60128066T patent/DE60128066T2/de not_active Expired - Lifetime
- 2001-01-31 AU AU2001234721A patent/AU2001234721B8/en not_active Ceased
- 2001-01-31 JP JP2001561057A patent/JP2003527109A/ja active Pending
- 2001-01-31 AU AU3472101A patent/AU3472101A/xx active Pending
- 2001-01-31 EP EP01906861A patent/EP1254174B1/en not_active Expired - Lifetime
- 2001-01-31 KR KR1020027009831A patent/KR100829842B1/ko not_active Expired - Fee Related
-
2002
- 2002-07-23 IL IL150885A patent/IL150885A/en active IP Right Grant
-
2008
- 2008-11-17 IL IL195337A patent/IL195337A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003527109A5 (enExample) | ||
| ES2372282T3 (es) | Método para detectar probnp con un anticuerpo monoclonal que fija los aminoácidos 38-43. | |
| US7670805B2 (en) | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 | |
| JP2002542157A5 (enExample) | ||
| JP2001511347A5 (enExample) | ||
| US20150111250A1 (en) | Methods and compositions for modulating tumor cell activity | |
| JP2004512022A5 (enExample) | ||
| WO2003093317A1 (en) | Antibody to human insulin-like growth factor | |
| JP2005505757A (ja) | 結合組織増殖因子の分析方法 | |
| JP2004536831A (ja) | 副甲状腺ホルモン抗体および関連した方法 | |
| Borsi et al. | Preparation of phage antibodies to the ED-A domain of human fibronectin | |
| JP2004501605A5 (enExample) | ||
| CA2635849A1 (en) | An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved | |
| US8753632B2 (en) | Antibodies to modified human IGF-1/E peptides | |
| CN114174341A (zh) | 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法 | |
| JP2008515388A5 (enExample) | ||
| JPH1066585A5 (enExample) | ||
| Campa et al. | Design of a novel small peptide targeted against a tumor-specific receptor | |
| JP2003510078A5 (enExample) | ||
| JP2021518748A (ja) | カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 | |
| JPH08502414A (ja) | ｐ５３蛋白断片とその疾患の検出およびモニタリングへの利用 | |
| JP5028269B2 (ja) | 生理活性インタクト副甲状腺ホルモン（ｐｔｈ）１−８４に対する選択的結合特異性を有する抗体および同抗体を作製するためのペプチド抗原 | |
| JP2005522228A5 (enExample) | ||
| JP3920556B2 (ja) | 短縮型ミッドカイン（ｔＭＫ）タンパク質特異的モノクローナル抗体及びその用途 | |
| JP2003510071A5 (enExample) |